Regado Biosciences   Report issue

For profit Phase 2 Phase 3
Founded: Durham NC United States (2001)
Status: Acquired by Tobira Therapeutics, Inc. (2015) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2007
NCT00715455
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Regado Biosciences, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

bivalirudin (angiomax) (1 trial)

pegnivacogin (4 trials)

Drugs in Phase 2 Trials (1)

heparin (liquaemin) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 2)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Myocardial Ischemia (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3